Short Interest in Forte Biosciences Rises 22.7%

Forte Biosciences, a biotech firm focused on skin health, sees increased short-selling activity.

Apr. 18, 2026 at 1:26am

Got story updates? Submit your updates here. ›

A high-contrast, cinematic close-up of the inner workings of a financial mechanism, such as gears, levers, and circuits, conveying the intricate and impersonal nature of modern finance without using any literal currency, charts, or text.As short interest in Forte Biosciences rises, the complex financial machinery behind the biotech company's stock performance is laid bare.San Diego Today

Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biotechnology company developing treatments for skin conditions, experienced a 22.7% increase in short interest during March. As of March 31st, 6.8% of the company's stock was being shorted, up from 5.5% on March 15th.

Why it matters

Short interest can indicate investor sentiment and speculation around a company's future performance. The rise in short interest for Forte Biosciences may signal that some investors are betting against the company's prospects, despite its focus on innovative skin health treatments.

The details

Forte Biosciences had short interest of 892,176 shares as of March 31st, up from 727,297 shares on March 15th. Based on the company's average daily trading volume of 254,336 shares, the days-to-cover ratio is now 3.5 days, meaning it would take short-sellers 3.5 days to cover their positions at the current volume.

  • As of March 31st, 2026, Forte Biosciences had 892,176 shares shorted.
  • On March 15th, 2026, Forte Biosciences had 727,297 shares shorted.

The players

Forte Biosciences, Inc.

A clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome.

Quadrature Capital Ltd

A large investor that bought a new stake in Forte Biosciences during the 4th quarter, worth approximately $479,000.

Millennium Management LLC

An investment management firm that boosted its holdings in Forte Biosciences by 105.9% in the fourth quarter, now owning 246,685 shares.

Janus Henderson Group PLC

An investment management company that increased its position in Forte Biosciences by 1.6% in the fourth quarter, now owning 1,425,785 shares.

683 Capital Management LLC

An investment firm that acquired a new stake in Forte Biosciences worth $1,091,000 in the fourth quarter.

Got photos? Submit your photos here. ›

The takeaway

The rise in short interest for Forte Biosciences, a biotech company focused on innovative skin health treatments, suggests some investors are betting against the company's future performance. However, the company continues to attract investment from major institutional players, indicating confidence in its long-term potential.